Health Care Equipment

ZHENDE MEDICAL

ZHENDE MEDICAL released FY2025 Q4 earnings on April 23 (BJT), actual revenue CNY 1.145 B, actual EPS CNY 0.2289

ZHENDE MEDICAL released FY2025 Annual Earnings on April 23 (BJT), actual revenue CNY 4.33 B (forecast CNY 4.766 B), actual EPS CNY 0.99 (forecast CNY 1.47)

ZHENDE MEDICAL released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 1 B, actual EPS CNY 0.2

ZHENDE MEDICAL to Release FY2026 Q1 Earnings on April 24 After-Market BJT

ZHENDE MEDICAL to Release FY2025 Annual Earnings on April 24, 2026 (BJT), Forecast Revenue CNY 4.766 B, EPS CNY 1.47

ZHENDE MEDICAL released FY2025 9 Months earnings on October 29 After-Market (BJT), actual revenue CNY 3.184 B, actual EPS CNY 0.7609

ZHENDE MEDICAL released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 1.084 B, actual EPS CNY 0.2796

ZHENDE MEDICAL to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

ZHENDE MEDICAL released FY2025 Semi-Annual earnings on August 27 After-Market (BJT), actual revenue CNY 2.1 B, actual EPS CNY 0.48

ZHENDE MEDICAL released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue CNY 1.109 B, actual EPS CNY 0.2913

ZHENDE MEDICAL to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

PROMEDEX signs MOU with Zhende Medical and MEDSURG

ZHENDE MEDICAL released FY2024 earnings on April 25 (BJT), actual revenue CNY 4.264 B (forecast CNY 4.494 B), actual EPS CNY 1.45 (forecast CNY 1.53)

ZHENDE MEDICAL released FY2024 Q4 earnings on April 25, 2025 (BJT), actual revenue CNY 1.138 B, actual EPS CNY 0.2983

ZhenDe Medical Reports Revenue Growth but Net Profit Decline in Q1

ZHENDE MEDICAL released FY2025 Q1 earnings on April 25 After-Market BJT, actual revenue CNY 991.56 M, actual EPS CNY 0.19

ZHENDE MEDICAL FY2025 Q1 Earnings Release Scheduled for April 26 After-Market BJT

ZHENDE MEDICAL to release FY2024 earnings on April 26, 2025 (BJT), forecast revenue CNY 4.494 B, EPS CNY 1.53

Zhend Medical Expects Net Profit Growth of 88% to 98% in 2024

Chairman Lu Jianguo of Zhend Medical States US Tariff Policy Has No Impact, Actively Seeking External Development Opportunities

SBUX

603301

Multinational corporations are increasingly adapting to China's dynamic consumer market by forming local alliances, joint ventures, or selling stakes to domestic partners. Examples include General Mills offloading Häagen-Dazs operations, Starbucks partnering with Boyu Capital, and Mölnlycke collaborating with Zhende Medical. Experts view these moves as essential strategies to leverage local expertise, remain competitive in the vast Chinese market, and gain insights applicable globally.

SCMP

General Mills

Starbucks

Citigroup

Restaurant Brands

Costco Wholesale

Walmart

Shake Shack

CITIGROUP INC 6.250 NON CUM SER II PFD WI

China’s fast-changing consumers force MNCs to adapt via local alliances

603786

This week's largest increase in margin financing balance: KEBODA margin financing balance: 449 million yuan, balance increase: 161.46%; ZHENDE MEDICAL margin financing balance: 544 million yuan, balance increase: 124.55%

Zhitong

KEBODA

ZHENDE MEDICAL rose 6.90% today, with a transaction amount of 1.109 billion yuan and a turnover rate of 11.48%. According to the after-hours dragon and tiger list data, the Shanghai Stock Connect special seat bought 52.3103 million yuan and sold 54.9025 million yuan, with 1 institutional special seat net selling 102 million yuan

ZHENDE MEDICAL rose 6.90% today, with one institutional special seat net selling 102 million yuan

ZHENDE MEDICAL's controlling shareholder Zhejiang ZHENDE and its wholly-owned subsidiary Xuchang Garden intend to transfer 5% of the company's shares, totaling 13.3226 million shares, at a transfer price of 26.74 yuan per share, with a total price of 356 million yuan. After the transfer, the shareholding ratio of the controlling shareholder and its concerted parties will decrease to 54.20%. The transferee Sun Jimu has committed not to reduce the acquired shares within 12 months

ZHENDE MEDICAL's controlling shareholder and concerted parties plan to transfer 5% of the company's shares through an agreement

The article discusses the resilience of smaller-cap stocks amid fluctuating global markets, highlighting Shanghai Yaohua Pilkington Glass Group and Zhende Medical as promising investments. Shanghai Yaohua has shown impressive earnings growth of 282.5% and improved debt management, while Zhende Medical reported a 188% earnings increase despite a slight dip in net income. Both companies are positioned for stability and growth, with strong fundamentals and strategic initiatives enhancing their market presence. The article emphasizes the importance of identifying undiscovered gems in the current economic landscape.

Simplywall

Global Undiscovered Gems Featuring Shanghai Yaohua Pilkington Glass Group And Two Promising Small Caps

ZHENDE MEDICAL announced that in the first half of 2025, operating revenue reached 2.1 billion yuan, a year-on-year increase of 2.83%. Net profit was 128 million yuan, a year-on-year decrease of 20.70%. The company will not distribute profits or convert capital reserves into share capital in the mid-term of 2025

ZHENDE MEDICAL: Net profit of 128 million yuan in the first half of 2025, a year-on-year decrease of 20.70%

ZHENDE MEDICAL announced that the company will repurchase 615,667 unvested shares due to the performance assessment of the first phase employee stock ownership plan not meeting the standards. The duration of the plan has been extended to January 2, 2026, and the funds for the repurchase will come from its own funds, which is expected not to adversely affect the company's financial condition and future development

ZHENDE MEDICAL: Plans to repurchase 615,667 unvested shares of the company

On the evening of April 25th, ZHENDE MEDICAL announced that it achieved operating revenue of 992 million yuan in the first quarter of 2025, a year-on-year increase of 2.87%; the net profit attributable to shareholders of the listed company was 51.2419 million yuan, a year-on-year decrease of 30.19%; basic earnings per share were 0.19 yuan

ZHENDE MEDICAL: In the first quarter, the net profit attributable to the parent company was 51.2419 million yuan, a year-on-year decrease of 30.19%

According to the Zhitong Finance APP, ZHENDE MEDICAL announced that the company expects to achieve a net profit attributable to shareholders of the listed company of between 373 million yuan and 393 million yuan for the year 2024, an increase of 174.6 million yuan to 194.6 million yuan compared to the same period last year, representing a year-on-year increase of 88.00% to 98.09%

ZHENDE MEDICAL issued a profit forecast, expecting a net profit of 373 million to 393 million yuan for the fiscal year 2024, an increase of 88% to 98.09% year-on-year

ZHENDE MEDICAL announced that it expects to achieve a net profit attributable to shareholders of the listed company of RMB 373 million to RMB 393 million for the year 2024, an increase of RMB 175 million to RMB 195 million compared to the same period last year, representing a year-on-year increase of 88.00% to 98.09%; it is expected that the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses will be RMB 303 million to RMB 323 million for the year 2024, an increase of RMB 113 million to RMB 133 million compared to the same period last year, representing a year-on-year increase of 59.82% to 70.37%

USHK News

ZHENDE MEDICAL: Expected net profit growth of 88.00% to 98.09% year-on-year in 2024

ZHENDE MEDICAL(603301.SH)